Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Synthesis of 2‐Acetamido‐1,3,4‐Tri‐O‐Acetyl‐2‐Deoxy‐D‐Mannopyranose ‐6‐Phosphate Prodrugs as potential therapeutic agents

Pertusati, Fabrizio ORCID: and Morewood, James 2022. Synthesis of 2‐Acetamido‐1,3,4‐Tri‐O‐Acetyl‐2‐Deoxy‐D‐Mannopyranose ‐6‐Phosphate Prodrugs as potential therapeutic agents. Current Protocols 2 (8) , e500. 10.1002/cpz1.500

[thumbnail of cpz1.500.pdf] PDF - Published Version
Download (502kB)


Abstract: Sugar phosphates are emerging as potential therapeutic candidates for certain diseases. However, their high polarity makes them poorly absorbed by the body and their penetration inside the cell is even more difficult without a proper transporter. Amino sugar phosphates (n‐amino‐n‐deoxy‐sugars, carbohydrates in which a hydroxyl group has been replaced with an amine group), such as N‐acetyl‐d‐mannosamine (ManNac)‐6‐phosphate have shown potential as a treatment for a muscular disease called GNE myopathy caused by a deficiency in the production of sialic acid. However, its high polarity leads to poor absorption and consequent high dosage in humans, causing unwanted side effects. Herein, we describe the application of phosphoramidate prodrug chemistry to 1,3,4‐O‐acetylated N‐acetylmannosamine (Ac3ManNAc) to deliver ManNAc‐6‐phosphate (ManNAc‐6‐P), a critical intermediate in sialic acid biosynthesis. Sialic acid deficiency is a hallmark of GNE myopathy, a rare congenital disorder of glycosylation (CDG), caused by mutations in the gene “GNE,” that limit the production of ManNAc‐6‐P. Synthetic methods were developed to provide a library of Ac3ManNAc‐6‐phosphoramidates that were evaluated in a series of studies for their potential as a treatment for GNE myopathy. © 2022 The Authors. Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Synthesis of 2‐Acetamido‐1,3,4‐tri‐O‐acetyl‐2‐deoxy‐d‐mannopyranose. Basic Protocol 2: Preparation of 3‐acetamido‐6‐((((((S)‐1‐ethoxy‐4‐methyl‐1‐oxo‐pentan‐2‐yl) amino) (phenoxy)phosphoryl) oxy) methyl) tetrahydro‐2H‐pyran‐2,4,5‐triyl triacetate (5). Support Protocol: Preparation of ethyl (chloro(phenoxy)phosphoryl)‐l‐leucinate.

Item Type: Article
Date Type: Published Online
Status: Published
Schools: Pharmacy
Additional Information: License information from Publisher: LICENSE 1: URL:
ISSN: 2691-1299
Date of First Compliant Deposit: 18 August 2022
Last Modified: 16 May 2023 12:28

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics